AZ-D933GC00002-EMERALD-Y90
Phase II
OPEN TO ACCRUAL
Phase II Single-Arm Study of Durvalumab and Bevacizumab Following Transarterial Radioembolization Using Yttrium-90 Glass Microspheres (TheraSphere) in Unresectable Hepatocellular Carcinoma Amenable to Locoregional Therapy
EXELIXIS-XL092-002
Phase I
OPEN TO ACCRUAL
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors
HOFFMANN-BO41932-TAPISTRY
Phase II
OPEN TO ACCRUAL
Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial
IIT-GEORGE-I-PREDICT
Phase I/II
OPEN TO ACCRUAL
An Open-Label, Navigational Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy for Patients with Aggressive Malignancies and Poor Prognoses
SOTIO-BOXR1030
Phase I/II
OPEN TO ACCRUAL *
A First-in-Human, Phase 1/2, Dose Escalation Study of BOXR1030 T Cells in Subjects with Advanced GPC3-Positive Solid Tumors
XILIO-XTX301-01-02-001
Phase I
OPEN TO ACCRUAL
A First-in-Human, Multicenter, Phase 1, Open-Label Study of XTX301 in Patients with Advanced Solid Tumors